Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 117, Issue 8, Pages 2186-2196Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI30398
Keywords
-
Categories
Funding
- NIAMS NIH HHS [R01 AR44894, R01 AR044894, R01 AR050812, R01 AR50812] Funding Source: Medline
Ask authors/readers for more resources
Though B cells play key roles in lupus pathogenesis, the molecular circuitry and its dysregulation in these cells as disease evolves remain poorly understood. To address this, a comprehensive scan of multiple signaling axes using multiplexed Western blotting was undertaken in several different murine lupus strains. PI3K/AKT/ mTOR (mTOR, mammalian target of rapamycin), MEK1/Erk1/2, p38, NF-kappa B, multiple Bcl-2 family members, and cell-cycle molecules were observed to be hyperexpressed in lupus B cells in an age-dependent and lupus susceptibility gene-dose-dependent manner. Therapeutic targeting of the AKT/mTOR axis using a rapamycin (sirolimus) derivative ameliorated the serological, cellular, and pathological phenotypes associated with lupus. Surprisingly, the targeting of this axis was associated with the crippling of several other signaling axes. These studies reveal that lupus pathogenesis is contingent upon the activation of an elaborate network of signaling cascades that is shared among genetically distinct mouse models and raise hope that targeting pivotal nodes in these networks may offer therapeutic benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available